Form 8-K - Current report:
SEC Accession No. 0001213900-13-006194
Filing Date
2013-11-12
Accepted
2013-11-12 07:30:51
Documents
3
Period of Report
2013-11-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k110813_actinium.htm 8-K 27973
2 PRESS RELEASE f8k110813ex99i_actinium.htm EX-99.1 10388
3 f8k110813ex99i_actinium0.jpg GRAPHIC 4017
  Complete submission text file 0001213900-13-006194.txt   45372
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52446 | Film No.: 131206964
SIC: 6770 Blank Checks